95%Confidence
0Views
FDASource
2026-04-07Date
Summary
A third Class II recall for Teva's Octreotide Acetate (30mg) confirms widespread sterility assurance failures across multiple dosages, severely impacting product reliability. This pattern suggests deep-rooted quality system deficiencies that may require significant remediation efforts and harm brand trust.
Actionable: Consider reducing exposure to Teva until comprehensive quality audits and corrective actions are confirmed.
AI Confidence: 95%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now